[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fdKH0gWidvg51yLO6mKaINpriwlOdHBTRUP99BEskeeA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":37,"rows":44},"University of Missouri, Kansas City",[4],47,false,8,4,7462,2,39,[14,16,18,20,22,24,27,29],{"name":15,"count":11},"Relapsing-remitting Multiple Sclerosis",{"name":17,"count":11},"Depression",{"name":19,"count":11},"Knee Osteoarthritis",{"name":21,"count":11},"Pregnancy",{"name":23,"count":11},"Multiple Sclerosis",{"name":25,"count":26},"Breast Cancer",1,{"name":28,"count":26},"Adolescent, Parenting",{"name":30,"count":26},"Arthritis",[32],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT04680221","Stopping Opioid Overuse in Obstetrics to Halt Exposure Trial","2025-06-01","Liposomal bupivacaine",[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,70,88,116,134,152,178,196,222,246,271,289,316,334,360],{"intervention":36,"totalTrials":26,"cells":46},{"EARLY_PHASE1":47,"PHASE1":50,"PHASE2":52,"PHASE3":54,"PHASE4":56,"NA":68},{"trials":48,"activeCount":49},[],0,{"trials":51,"activeCount":49},[],{"trials":53,"activeCount":49},[],{"trials":55,"activeCount":49},[],{"trials":57,"activeCount":26,"soonestReadout":35},[58],{"nctId":33,"briefTitle":34,"status":59,"phases":60,"primaryCompletion":35,"completion":35,"start":61,"enrollment":62,"conditions":63,"interventions":66},"ACTIVE_NOT_RECRUITING",[42],"2021-03-01",97,[64,65],"Pain, Postoperative","Opioid Use",[36,67],"Deposition of saline",{"trials":69,"activeCount":49},[],{"intervention":67,"totalTrials":26,"cells":71},{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":86},{"trials":73,"activeCount":49},[],{"trials":75,"activeCount":49},[],{"trials":77,"activeCount":49},[],{"trials":79,"activeCount":49},[],{"trials":81,"activeCount":26,"soonestReadout":35},[82],{"nctId":33,"briefTitle":34,"status":59,"phases":83,"primaryCompletion":35,"completion":35,"start":61,"enrollment":62,"conditions":84,"interventions":85},[42],[64,65],[36,67],{"trials":87,"activeCount":49},[],{"intervention":89,"totalTrials":26,"cells":90},"Acetaminophen",{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":99,"NA":114},{"trials":92,"activeCount":49},[],{"trials":94,"activeCount":49},[],{"trials":96,"activeCount":49},[],{"trials":98,"activeCount":49},[],{"trials":100,"activeCount":49},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":111},"NCT00484744","Acetaminophen Versus Ibuprofen for the Control of Immediate and Delayed Pain Following Orthodontic Separator Placement","COMPLETED",[42],"2008-01","2007-06",35,[110],"Orthodontic Pain",[89,112,113],"Avicel","Ibuprofen",{"trials":115,"activeCount":49},[],{"intervention":112,"totalTrials":26,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":132},{"trials":119,"activeCount":49},[],{"trials":121,"activeCount":49},[],{"trials":123,"activeCount":49},[],{"trials":125,"activeCount":49},[],{"trials":127,"activeCount":49},[128],{"nctId":102,"briefTitle":103,"status":104,"phases":129,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":130,"interventions":131},[42],[110],[89,112,113],{"trials":133,"activeCount":49},[],{"intervention":113,"totalTrials":26,"cells":135},{"EARLY_PHASE1":136,"PHASE1":138,"PHASE2":140,"PHASE3":142,"PHASE4":144,"NA":150},{"trials":137,"activeCount":49},[],{"trials":139,"activeCount":49},[],{"trials":141,"activeCount":49},[],{"trials":143,"activeCount":49},[],{"trials":145,"activeCount":49},[146],{"nctId":102,"briefTitle":103,"status":104,"phases":147,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":148,"interventions":149},[42],[110],[89,112,113],{"trials":151,"activeCount":49},[],{"intervention":153,"totalTrials":26,"cells":154},"Azithromycin",{"EARLY_PHASE1":155,"PHASE1":157,"PHASE2":159,"PHASE3":161,"PHASE4":163,"NA":176},{"trials":156,"activeCount":49},[],{"trials":158,"activeCount":49},[],{"trials":160,"activeCount":49},[],{"trials":162,"activeCount":49},[],{"trials":164,"activeCount":49},[165],{"nctId":166,"briefTitle":167,"status":168,"phases":169,"primaryCompletion":170,"completion":170,"start":171,"enrollment":49,"conditions":172,"interventions":174},"NCT01721616","Comparison Study of Cefazolin Versus Cefazolin Plus Azithromycin Prophylaxis in Post-Cesarean Endometritis","WITHDRAWN",[42],"2014-11","2012-11",[173],"Endometritis",[153,175],"Cefazolin",{"trials":177,"activeCount":49},[],{"intervention":175,"totalTrials":26,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":188,"NA":194},{"trials":181,"activeCount":49},[],{"trials":183,"activeCount":49},[],{"trials":185,"activeCount":49},[],{"trials":187,"activeCount":49},[],{"trials":189,"activeCount":49},[190],{"nctId":166,"briefTitle":167,"status":168,"phases":191,"primaryCompletion":170,"completion":170,"start":171,"enrollment":49,"conditions":192,"interventions":193},[42],[173],[153,175],{"trials":195,"activeCount":49},[],{"intervention":197,"totalTrials":26,"cells":198},"amitriptyline",{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":218,"NA":220},{"trials":200,"activeCount":49},[],{"trials":202,"activeCount":49},[],{"trials":204,"activeCount":49},[],{"trials":206,"activeCount":49},[207],{"nctId":208,"briefTitle":209,"status":210,"phases":211,"primaryCompletion":212,"completion":212,"start":213,"enrollment":26,"conditions":214,"interventions":217},"NCT04725383","Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders","TERMINATED",[41],"2025-05-23","2023-11-01",[215,216],"Autism Spectrum Disorder","Repetitive Compulsive Behavior",[197],{"trials":219,"activeCount":49},[],{"trials":221,"activeCount":49},[],{"intervention":223,"totalTrials":26,"cells":224},"armodafinil",{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":231,"PHASE4":242,"NA":244},{"trials":226,"activeCount":49},[],{"trials":228,"activeCount":49},[],{"trials":230,"activeCount":49},[],{"trials":232,"activeCount":49},[233],{"nctId":234,"briefTitle":235,"status":104,"phases":236,"primaryCompletion":237,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":241},"NCT00981084","Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)",[40,41],"2011-04","2009-09",33,[23],[223],{"trials":243,"activeCount":49},[],{"trials":245,"activeCount":49},[],{"intervention":247,"totalTrials":26,"cells":248},"Intravenous heparin",{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":255,"PHASE4":257,"NA":259},{"trials":250,"activeCount":49},[],{"trials":252,"activeCount":49},[],{"trials":254,"activeCount":49},[],{"trials":256,"activeCount":49},[],{"trials":258,"activeCount":49},[],{"trials":260,"activeCount":49},[261],{"nctId":262,"briefTitle":263,"status":168,"phases":264,"primaryCompletion":265,"completion":265,"start":266,"enrollment":49,"conditions":267,"interventions":269},"NCT00657228","Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department",[43],"2010-12","2009-12",[268],"Anaphylaxis",[247,270],"Saline",{"intervention":270,"totalTrials":26,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":283},{"trials":274,"activeCount":49},[],{"trials":276,"activeCount":49},[],{"trials":278,"activeCount":49},[],{"trials":280,"activeCount":49},[],{"trials":282,"activeCount":49},[],{"trials":284,"activeCount":49},[285],{"nctId":262,"briefTitle":263,"status":168,"phases":286,"primaryCompletion":265,"completion":265,"start":266,"enrollment":49,"conditions":287,"interventions":288},[43],[268],[247,270],{"intervention":290,"totalTrials":26,"cells":291},"Glutamine",{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":300,"NA":302},{"trials":293,"activeCount":49},[],{"trials":295,"activeCount":49},[],{"trials":297,"activeCount":49},[],{"trials":299,"activeCount":49},[],{"trials":301,"activeCount":49},[],{"trials":303,"activeCount":49},[304],{"nctId":305,"briefTitle":306,"status":104,"phases":307,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":314},"NCT01239680","Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy",[43],"2013-11","2013-12","2011-01",5,[313],"Hemorrhagic Shock",[290,315],"Ringer's Lactate",{"intervention":315,"totalTrials":26,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":324,"PHASE4":326,"NA":328},{"trials":319,"activeCount":49},[],{"trials":321,"activeCount":49},[],{"trials":323,"activeCount":49},[],{"trials":325,"activeCount":49},[],{"trials":327,"activeCount":49},[],{"trials":329,"activeCount":49},[330],{"nctId":305,"briefTitle":306,"status":104,"phases":331,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":332,"interventions":333},[43],[313],[290,315],{"intervention":335,"totalTrials":26,"cells":336},"Timolol eye drops",{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":345,"NA":347},{"trials":338,"activeCount":49},[],{"trials":340,"activeCount":49},[],{"trials":342,"activeCount":49},[],{"trials":344,"activeCount":49},[],{"trials":346,"activeCount":49},[],{"trials":348,"activeCount":49},[349],{"nctId":350,"briefTitle":351,"status":210,"phases":352,"primaryCompletion":353,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":358},"NCT02630719","Timolol Eye Drops in the Treatment of Acute Migraine Headache",[43],"2017-08-01","2016-01",10,[357],"Migraine",[335,359],"Artificial tears",{"intervention":359,"totalTrials":26,"cells":361},{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":370,"NA":372},{"trials":363,"activeCount":49},[],{"trials":365,"activeCount":49},[],{"trials":367,"activeCount":49},[],{"trials":369,"activeCount":49},[],{"trials":371,"activeCount":49},[],{"trials":373,"activeCount":49},[374],{"nctId":350,"briefTitle":351,"status":210,"phases":375,"primaryCompletion":353,"completion":353,"start":354,"enrollment":355,"conditions":376,"interventions":377},[43],[357],[335,359]]